AKT1 and leukemia: Clinical trials are already underway or completed for drugs like, AKT inhibitor, MK-2206, for CLL/SLL and relapse/refractory leukemias or lymphomas, while mTOR inhibitors sirolimus (rapamycin) and everolimus are being used in clinical trials.